Personalised Medicine - Bespoke Healthcare is the Latest Trend
Keywords:
MedicineAbstract
NIL
References
1 European Science Foundation. Personalised Medicine for the European Citizen - towards more precise medicine for the diagnosis, treatment and prevention of disease. (2015). Available at: http://www.esf.org/index.php?elD=tx_nawse- curedl&u=0&file=fileadmin/be_user/CEO_Unit/Forward_Look/ iPM.pdf&t=1426213045&hash=ce6cb2ebd43e2a11bb16071b- 12110514325c5b08 (Acessed: 12th March 2015).
2 Welter D, et al. The NHGRI GWAS Catalog, a curated re-source of SNP-trait associations. Nucleic Acids Res. 2014;42:1001– 1006.
3 Ortega VE, Meyers DA, Bleecker ER. Asthma pharmaco- genetics and the development
of genetic profiles for personalized medicine. Pharmgenomics Pers. Med. 2015;8:9-22.
4 Shukla S, Bhargava S, Somasundaram K. Cancer gene signatures in risk stratification: use in personalized medicine. Curr. Sci. 2014;107(5):815-823.
5 Piccart-Gebhart MJ, Sotiriou C, Adjuvant chemotherapy – yes or no? Prognostic markers in early breast cancer. Ann. On- col. 2007;18(12):2–7.
6 Cusumano PG, et al. European inter-institutional im- pact study of MammaPrint. Breast. 2014;23:423-428
7 Abul-Husn NS, et al. Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers. Med. 2014;7:227–240.
8 Personalised Medicine Coalition. The Case for Personalized Medicine (4th Edition; 2014) Available at: http://www.per- sonalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/ pmc_the_case_for_personalized_medicine.pdf (Accessed: 12th March 2015).
9 Bosch R, Rosich L, The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize. Pharmacology. 2008;82(3):171–179.
10 Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
11 National Centre for Pharmacoeconomics. Cost-effectiveness of Ivacaftor (KalydecoTM) for the
treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation. (2013) Available at: http://www.ncpe. ie/wp-content/uploads/2012/08/Ivacaftor-Summary.pdf (Accessed: 11th March 2015).
2 Welter D, et al. The NHGRI GWAS Catalog, a curated re-source of SNP-trait associations. Nucleic Acids Res. 2014;42:1001– 1006.
3 Ortega VE, Meyers DA, Bleecker ER. Asthma pharmaco- genetics and the development
of genetic profiles for personalized medicine. Pharmgenomics Pers. Med. 2015;8:9-22.
4 Shukla S, Bhargava S, Somasundaram K. Cancer gene signatures in risk stratification: use in personalized medicine. Curr. Sci. 2014;107(5):815-823.
5 Piccart-Gebhart MJ, Sotiriou C, Adjuvant chemotherapy – yes or no? Prognostic markers in early breast cancer. Ann. On- col. 2007;18(12):2–7.
6 Cusumano PG, et al. European inter-institutional im- pact study of MammaPrint. Breast. 2014;23:423-428
7 Abul-Husn NS, et al. Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers. Med. 2014;7:227–240.
8 Personalised Medicine Coalition. The Case for Personalized Medicine (4th Edition; 2014) Available at: http://www.per- sonalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/ pmc_the_case_for_personalized_medicine.pdf (Accessed: 12th March 2015).
9 Bosch R, Rosich L, The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize. Pharmacology. 2008;82(3):171–179.
10 Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
11 National Centre for Pharmacoeconomics. Cost-effectiveness of Ivacaftor (KalydecoTM) for the
treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation. (2013) Available at: http://www.ncpe. ie/wp-content/uploads/2012/08/Ivacaftor-Summary.pdf (Accessed: 11th March 2015).
Downloads
Published
2015-01-01
How to Cite
Mangan, L. (2015). Personalised Medicine - Bespoke Healthcare is the Latest Trend. Trinity Student Medical Journal , 16(1), Page 6–8. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1868
Issue
Section
Editorials
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
